Alle biotech stijgt. Niets aan de hand.
Laatste artikelen op Beursig.com
Meer info en details in de PDF, via onderstaande linkInventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast event
9 June 2021
Daix (France), June 9, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that three abstracts have been selected for presentation at the upcoming International Liver CongressTM 2021 hosted by the European Association for the Study of the Liver (EASL), June 23-26, 2021. Inventiva will also host a KOL webcast event on June 29, 2021, focusing on the three abstracts, the current NASH field and Inventiva’s upcoming Phase III clinical trial on lanifibranor (further details below).
The first abstract focusing on the beneficial effects of lanifibranor on cardiovascular risk biomarkers has been selected for an oral presentation. Based on the results of Inventiva’s NATIVE Phase IIb clinical trial evaluating lanifibranor in NASH, the authors of the abstract analyzed the change in the cardiovascular risk profile in patients with NASH by measuring several serum biomarkers. Lanifibranor showed beneficial effects on several cardiovascular risk biomarkers, including dyslipidemia, insulin resistance, inflammation and high blood pressure, confirming its promising profile as a potential treatment for NASH.
+ 7% in US, of toch ietsje meer dan een doodnormale koersschommeling
Aandelen / beurzen
Tools / technische analyse